Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.53 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 6/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 2/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.45 |
| ▸ | REN | P00797 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15569444 | 1.00 | CTSS (0.53) | CTSSPPARASYKPPARGCTSK | |
| SCHEMBL16925147 | 1.00 | CTSS (0.53) | CTSSPPARASYKPPARGCTSK | |
| SCHEMBL15568625 | 0.97 | CTSS (0.55) | CTSSPPARASYKPPARGCTSK | |
| SCHEMBL15568621 | 0.97 | CTSS (0.55) | CTSSPPARASYKPPARGCTSK | |
| SCHEMBL16984839 | 0.97 | CTSS (0.55) | CTSSPPARASYKPPARGCTSK | |
| SCHEMBL16984877 | 0.93 | CTSS (0.55) | CTSSPPARACTSKCTSLCTSB | |
| SCHEMBL15570214 | 0.93 | PPARA (0.57) | CTSSPPARASYKPPARGCTSK | |
| SCHEMBL15569220 | 0.93 | PPARA (0.57) | CTSSPPARASYKPPARGCTSK | |
| SCHEMBL8138593 | 0.93 | CTSS (0.59) | CTSSPPARASYKPPARGCTSK | |
| SCHEMBL16984916 | 0.92 | CTSK (0.56) | CTSSCTSKCTSLCTSBREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-12-01 | — | — | US | disclosed |
| US-9441012-B2 | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors | TRILLIUM THERAPEUTICS INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| US-20150203534-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | FLUORINOV PHARMA INC. (CA) | 2015-07-23 | — | — | US | disclosed |
| EP-2885314-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | Fluorinov Pharma Inc. (CA) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014026282-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | SLASSI ABDELMALIK (CA) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB7 | CTSS 1116/4885PPARA 2426/4885SYK 3227/4885 |
| US-20150203534-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB7 | CTSS 1197/4885PPARA 2465/4885SYK 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.